Pramipexole

Routes
Oral (PO)
Half-Life (t½)
PO: 8h
Formula
C10H17N3S
Molecular Weight
211.33 g/mol
PubChem CID
119570
Aliases
Mirapex

Pharmacological Mechanism

Non-ergot dopamine agonist with preferential affinity for the D3 receptor (within the D2 receptor family); first-line for Parkinson's disease and restless legs syndrome.

Half-Life & Elimination Curve (PO: 8h)

100%50%25%12.5%0%0h0×t½8h1×t½16h2×t½24h3×t½32h4×t½40h5×t½0×t½ (0h): 100% remaining (~0.756 µg/L)1×t½ (8h): 50% remaining (~0.378 µg/L)2×t½ (16h): 25% remaining (~0.189 µg/L)3×t½ (24h): 12.5% remaining (~0.0945 µg/L)4×t½ (32h): 6.3% remaining (~0.0472 µg/L)5×t½ (40h): 3.1% remaining (~0.0236 µg/L)
Plasma (PO)t½ Decay (8h)Effect Site (ke0)
  • 0×t½0h100% (0.756 µg/L)
  • 1×t½8h50% (0.378 µg/L)
  • 2×t½16h25% (0.189 µg/L)
  • 3×t½24h12.5% (0.0945 µg/L)
  • 4×t½32h6.3% (0.0472 µg/L)
  • 5×t½40h3.1% (0.0236 µg/L)
Elimination t½8h (PO)
Rate Constant (ke)0.0866 h⁻¹
Time to Peak (Tmax)2.02h
Est. Peak (Cmax)0.756 µg/L
Clearance (CL)43.3 L/h
97% Washout (5×t½)40h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Target Organ Systems

Notes

PK from FDA prescribing information (DailyMed setid 46f88017-7b0e-437e-90b1-37bdf9013e72): absolute bioavailability >90% (F 0.9), apparent Vd ~500 L, terminal t½ ~8 h (young)/~12 h (elderly), Tmax ~2 h, ~90% excreted unchanged in urine. ka_hr 1.5 derived from Tmax 2 h (ke from t½ 8 h). Human D2 affinity not authored — GtoPdb's curated human range (pKi 5.1–7.4) is too wide to pin a value.

Chemical Structure & Identifiers

References